AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL. It also provides MAVYRET to treat patients with chronic HCV genotype 1-6 infection, CREON for exocrine pancreatic insufficiency, Synthroid for hypothyroidism, Linzess/Constella for irritable bowel syndrome with constipation and chronic idiopathic constipation, Lupron for the palliative treatment of advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids, and Botox therapeutic. In addition, the company offers ORILISSA for moderate to severe endometriosis pain, Duopa and Duodopa for Parkinson's disease, Lumigan/Ganfort for elevated intraocular pressure, Ubrelvy for migraine, Alphagan/Combigan for ocular hypertension, and Restasis to increase tear production. AbbVie has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Symbol | ABBV |
|---|---|
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| CEO | Robert A. Michael |
| Employees | 55000 |
| Headquarters | North Chicago, IL, US |
| IPO | 2013-01-02 |
| Website | www.abbvie.com |